Dr Guilherme Perini speaks to ecancer about results from the KEYFORM-008 trial evaluating the combination of favezelimab, a LAG-3 inhibitor, and pembrolizumab in patients with relapsed or refractory classic Hodgkin lymphoma whose disease had progressed on prior PD-1-directed therapy.

He reports that the combination significantly improved progression-free survival compared with chemotherapy, with a higher proportion of patients remaining progression-free at 12 months and a longer duration of response.

Dr Perini explains that although objective response rates were lower with favezelimab and pembrolizumab than with chemotherapy, overall disease control was similar between the treatment groups and responses were more durable with the immunotherapy combination.